FDAnews
www.fdanews.com/articles/98165-schering-plough-merck-joint-venture-files-nda-for-allergic-rhinitis-drug

Schering-Plough/Merck Joint Venture Files NDA for Allergic Rhinitis Drug

September 6, 2007

Schering-Plough/Merck Pharmaceuticals, a joint venture between Schering-Plough and Merck, announced that the FDA has accepted its new drug application filing for an allergic rhinitis drug.

The drug combines the active ingredients of Schering-Plough’s Claritin (loratadine) and Merck’s Singulair (montelukast sodium), both of which are indicated for the relief of allergic rhinitis symptoms.

Schering-Plough/Merck Pharmaceuticals is seeking U.S. marketing approval for the combined loratadine/montelukast drug, which would be available by prescription and would be used to relieve nasal congestion in allergic rhinitis patients. The joint venture was formed in May 2000 specifically to develop and market respiratory treatment products.